Failure of alpha-galactosylceramide to prevent diabetes in virus-inducible models of type 1 diabetes in the rat.
Document Type
Article
Publication Date
2009
Keywords
CD4-Positive-T-Lymphocytes, CD8-Positive-T-Lymphocytes, Diabetes-Mellitus-Type-1, Disease-Models-Animal, Galactosylceramides, Interferon-gamma, Interleukin-12, Interleukin-4, Mice-Inbred-C57BL, Mice-Inbred-NOD, Rats, Sex-Factors, Spleen
First Page
195
Last Page
201
JAX Location
see Reprint Collection (a pdf is available)
JAX Source
In Vivo 2009 Mar-Apr; 23(2):195-201.
Abstract
BACKGROUND: Alpha-galactosylceramide (alpha-GalCer) is an invariant natural killer T (iNKT) cell ligand that prevents type 1 diabetes in NOD mice. However, alpha-GalCer can activate or suppress immune responses, raising concern about its potential use in human diabetes. MATERIALS AND METHODS: To evaluate this therapeutic issue further, BBDR and LEW.1WR1 rats were treated with Kilham rat virus (KRV) plus polyinosinic-polycytidylic acid, with or without alpha-GalCer, and followed for onset of diabetes. RESULTS: alpha-GalCer did not prevent diabetes in inducible rat models. To investigate this discrepancy, we analyzed iNKT cell function. Splenocytes stimulated with alpha-GalCer produced similar levels of IFNgamma in all rat strains, but less than mouse splenocytes. Rat splenocytes stimulated with alpha-GalCer preferentially produced IL-12, whereas mouse splenocytes preferentially produced IL-4. CONCLUSION: alpha-GalCer elicits species-specific cytokine responses in iNKT cells. In humans with type 1 diabetes, differences in iNKT cell responses to stimulation with alpha-GalCer due to age, genetic variability and other factors may influence its therapeutic potential.
Recommended Citation
Chopra P,
Diiorio P,
Pino SC,
Wilson SB,
Phillips NE,
Mordes JP,
Rossini AA,
Greiner DL,
Shultz LD,
Bortell R.
Failure of alpha-galactosylceramide to prevent diabetes in virus-inducible models of type 1 diabetes in the rat. In Vivo 2009 Mar-Apr; 23(2):195-201.